Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-DTPA-Isoquinoline
- Development stage
- Preclinical
- Lead developer
- Defence Research and Development Organisation
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
99mTc-DTPA-Isoquinoline (also known as 99mTc-THQ-DTPA) is a technetium-99m labeled radiopharmaceutical developed as a single-photon emission computed tomography (SPECT) imaging agent. It consists of an isoquinoline-based ligand conjugated to diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with technetium-99m. The agent specifically targets the sigma-2 receptor, which is highly overexpressed in rapidly proliferating cancer cells, particularly in breast tumors. Developed by researchers at the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO) in India, in collaboration with other institutions, this diagnostic tracer is being evaluated in preclinical models for the early detection and imaging of breast cancer, including triple-negative breast cancer.
- Other names
- 99mTc-DTPA-isoquinoline99mTc-tris(carboxymethyl)-1-(6,7-dimethoxy-3,4-dihydro isoquinoline-2(1H)-yl)-4-oxo-3,6,8,11,14-pentaazahexadecan-16-oic acid99mTc-tris(carboxymethyl)-1-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)-4-oxo-3,6,8,11,14-pentaazahexadecan-16-oic acid
02
Targets
TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))
Beyond the preview
Go deeper on 99mTc-DTPA-Isoquinoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-DTPA-Isoquinoline.